• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CTS Corporation Announces Appointment of Amy M. Dodrill to its Board of Directors

    2/8/24 5:30:00 PM ET
    $CTS
    $PRCT
    Electrical Products
    Technology
    Medical/Dental Instruments
    Health Care
    Get the next $CTS alert in real time by email

    LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees.

    Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical Solutions and Patient Support Systems segment, a $2 billion business with innovative products focused on advancing connected care and patient outcomes. In that role, Ms. Dodrill successfully integrated two former Hillrom business units into Baxter. Ms. Dodrill is a member of the board of directors of Procept BioRobotics (NASDAQ:PRCT), a commercial stage surgical robotics company, serving on the audit and compensation committees.

    "CTS is pleased to welcome Amy Dodrill to the CTS board.   Her extensive experience in the medical end market and background leading global businesses make her a valuable addition to our already highly experienced and diverse group of directors as CTS continues to focus on growth, end-market diversification, and products that sense, connect and move," said Kieran O'Sullivan, Chairman, President and CEO of CTS.

    About CTS

    CTS (NYSE:CTS) is a leading designer and manufacturer of products that Sense, Connect, and Move. The company manufactures sensors, actuators, and electronic components in North America, Europe, and Asia, and provides engineered products to customers in the aerospace/defense, industrial, medical, and transportation markets. For more information, visit www.ctscorp.com.

    Contact

    Ashish Agrawal

    Vice President and Chief Financial Officer

    CTS Corporation

    4925 Indiana Avenue

    Lisle, IL 60532

    USA

    Telephone: +1 (630) 577-8800

    Email: [email protected]



    Primary Logo

    Get the next $CTS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTS
    $PRCT

    CompanyDatePrice TargetRatingAnalyst
    PROCEPT BioRobotics Corporation
    $PRCT
    9/2/2025$60.00Perform → Outperform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    7/9/2025$70.00Overweight
    Stephens
    PROCEPT BioRobotics Corporation
    $PRCT
    7/7/2025Perform
    Oppenheimer
    PROCEPT BioRobotics Corporation
    $PRCT
    12/2/2024$105.00Overweight
    Morgan Stanley
    PROCEPT BioRobotics Corporation
    $PRCT
    11/14/2024$95.00Hold
    Jefferies
    CTS Corporation
    $CTS
    2/7/2024$46.00Buy → Neutral
    Sidoti
    CTS Corporation
    $CTS
    2/7/2024$38.00 → $46.00Market Perform
    TD Cowen
    PROCEPT BioRobotics Corporation
    $PRCT
    8/11/2023$42.00Overweight
    Piper Sandler
    More analyst ratings

    $CTS
    $PRCT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    PROCEPT BioRobotics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded PROCEPT BioRobotics from Perform to Outperform and set a new price target of $60.00

    9/2/25 8:22:53 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Stephens initiated coverage on PROCEPT BioRobotics with a new price target

    Stephens initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $70.00

    7/9/25 8:44:45 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Oppenheimer initiated coverage on PROCEPT BioRobotics

    Oppenheimer initiated coverage of PROCEPT BioRobotics with a rating of Perform

    7/7/25 8:02:36 AM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CTS
    $PRCT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CTS
    $PRCT
    SEC Filings

    View All

    $CTS
    $PRCT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CTS Corporation Declares a Dividend and Share Repurchase Program

    LISLE, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on January 23, 2026, to shareholders of record at the close of business on December 26, 2025. CTS Corporation also announced a new share repurchase program authorizing the company to buy back up to $100 million of its common stock. This program replaces the prior share repurchase program that was approved in February 2024. The program has no set expiration date and allows for repurchases to be made from time to time in the open market or through privately negotiated transact

    11/7/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    CTS Corporation Announces Appointment of Kimberly Banks MacKay to its Board of Directors

    LISLE, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Kimberly Banks MacKay has been appointed to its Board of Directors, effective November 5, 2025, and that she will serve as a member of the Nominating, Governance and Sustainability Committee, as well as the Technology and Transactions Committee. Ms. MacKay comes to CTS with over 30 years of experience driving results in multi-national companies serving key end markets. Ms. MacKay currently serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services, Inc. Ms. MacKa

    11/6/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

    SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $44.4 million for the third quarter of 2025, an increase of 50% compared to the prior year period in 2024The installed base in the U.S. increased by 58 robotic systems in the third quarter of 2025U.S

    11/4/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Zulueta Alfonso G was granted 3,500 shares, increasing direct ownership by 11% to 35,913 units (SEC Form 4)

    4 - CTS CORP (0000026058) (Issuer)

    11/10/25 4:11:19 PM ET
    $CTS
    Electrical Products
    Technology

    Director Stone Randy Lee was granted 3,500 shares, increasing direct ownership by 40% to 12,200 units (SEC Form 4)

    4 - CTS CORP (0000026058) (Issuer)

    11/10/25 4:08:31 PM ET
    $CTS
    Electrical Products
    Technology

    Director Profusek Robert was granted 3,500 shares, increasing direct ownership by 4% to 101,742 units (SEC Form 4)

    4 - CTS CORP (0000026058) (Issuer)

    11/10/25 4:07:11 PM ET
    $CTS
    Electrical Products
    Technology

    CTS Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - CTS CORP (0000026058) (Filer)

    11/6/25 9:00:28 AM ET
    $CTS
    Electrical Products
    Technology

    SEC Form 10-Q filed by PROCEPT BioRobotics Corporation

    10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)

    11/5/25 5:15:22 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    PROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)

    11/4/25 4:09:53 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Moll Frederic H bought $785,138 worth of shares (20,000 units at $39.26), increasing direct ownership by 2% to 863,159 units (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    8/14/25 4:18:26 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    $CTS
    $PRCT
    Financials

    Live finance-specific insights

    View All

    CTS Corporation Declares a Dividend and Share Repurchase Program

    LISLE, Ill., Nov. 07, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of CTS Corporation (NYSE:CTS) has declared a cash dividend of $0.04 per share on outstanding shares of common stock, without par value, to be paid on January 23, 2026, to shareholders of record at the close of business on December 26, 2025. CTS Corporation also announced a new share repurchase program authorizing the company to buy back up to $100 million of its common stock. This program replaces the prior share repurchase program that was approved in February 2024. The program has no set expiration date and allows for repurchases to be made from time to time in the open market or through privately negotiated transact

    11/7/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance

    SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2025. Recent Highlights Total revenue of $83.3 million for the third quarter of 2025, an increase of 43% compared to the prior year period in 2024U.S. handpiece and consumables revenue of $44.4 million for the third quarter of 2025, an increase of 50% compared to the prior year period in 2024The installed base in the U.S. increased by 58 robotic systems in the third quarter of 2025U.S

    11/4/25 4:03:00 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    CTS Announces Third Quarter 2025 Results

    LISLE, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced third quarter 2025 results. "Our business had another quarter of strong growth with sales up 22% year over year in the diversified end markets. The CTS team executed well in a challenging environment achieving solid profitability and strong cash generation," said Kieran O'Sullivan, CEO of CTS Corporation. "Diversification remains a strategic priority to drive growth and margin expansion." Third Quarter 2025 Results Sales were $143 million in the third quarter of 2025, up 8% year-over-yea

    10/28/25 8:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    $CTS
    $PRCT
    Leadership Updates

    Live Leadership Updates

    View All

    CTS Corporation Announces Appointment of Kimberly Banks MacKay to its Board of Directors

    LISLE, Ill., Nov. 06, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Kimberly Banks MacKay has been appointed to its Board of Directors, effective November 5, 2025, and that she will serve as a member of the Nominating, Governance and Sustainability Committee, as well as the Technology and Transactions Committee. Ms. MacKay comes to CTS with over 30 years of experience driving results in multi-national companies serving key end markets. Ms. MacKay currently serves as SVP, General Counsel and Corporate Secretary of West Pharmaceutical Services, Inc. Ms. MacKa

    11/6/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    CTS Corporation Announces the Appointment of Mark Pacioni as Chief Legal & Administrative Officer and Corporate Secretary

    LISLE, Ill., July 01, 2025 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS) today announced that Mark Pacioni has been appointed Chief Legal & Administrative Officer and Corporate Secretary, effective July 1, 2025. Prior to joining CTS, Mr. Pacioni served as Chief Legal Officer and Secretary of CareerBuilder, LLC from 2019 to 2024 and its successor company, CareerBuilder + Monster, from 2024 until June 2025. Prior thereto, he held senior legal roles at The Boeing Co., Molex, Inc., and Knowles Corp. In addition to his in-house experience, Mr. Pacioni was in private practice representing public companies on transactions and governance matters and was Special Counsel at the U.S. Securities and

    7/1/25 9:00:00 AM ET
    $CTS
    Electrical Products
    Technology

    Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

    SAN CARLOS, Calif., Oct. 28, 2024 /PRNewswire/ -- Sonder Capital, a leading healthcare venture firm focused on innovative technologies ushering in a new standard of care in medicine, announced the addition of Deborah Kilpatrick, Ph.D., former CEO of Evidation Health and co-founder of MedtechWomen, as a Venture Partner. Kilpatrick earned her Ph.D. from Georgia Tech in mechanical engineering with a focus in bioengineering and a minor in applied mathematics. Most recently, she was the CEO and Executive Chair of the Board at Evidation Health, a technology company that pioneered th

    10/28/24 7:00:00 AM ET
    $ISRG
    $PRCT
    $SNBR
    Industrial Specialties
    Health Care
    Medical/Dental Instruments
    Home Furnishings

    $CTS
    $PRCT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PROCEPT BioRobotics Corporation

    SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)

    11/14/24 1:28:32 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by CTS Corporation

    SC 13G/A - CTS CORP (0000026058) (Subject)

    11/14/24 1:28:29 PM ET
    $CTS
    Electrical Products
    Technology

    SEC Form SC 13G filed by CTS Corporation

    SC 13G - CTS CORP (0000026058) (Subject)

    11/14/24 12:28:26 PM ET
    $CTS
    Electrical Products
    Technology